Patents by Inventor Charles G. Cerveny

Charles G. Cerveny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD19 BINDING AGENTS AND USES THEREOF
    Publication number: 20230033859
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: March 8, 2022
    Publication date: February 2, 2023
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD19 binding agents and uses thereof
    Patent number: 11331394
    Abstract: This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: May 17, 2022
    Assignee: SEAGEN INC.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD19 BINDING AGENTS AND USES THEREOF
    Publication number: 20180326087
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: February 14, 2018
    Publication date: November 15, 2018
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD19 binding agents and uses thereof
    Patent number: 9919061
    Abstract: This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: March 20, 2018
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD19 BINDING AGENTS AND USES THEREOF
    Publication number: 20180000961
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: June 18, 2015
    Publication date: January 4, 2018
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD19 BINDING AGENTS AND USES THEREOF
    Publication number: 20150283255
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: June 18, 2015
    Publication date: October 8, 2015
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
    Patent number: 9101609
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: August 11, 2015
    Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
  • CD19 binding agents and uses thereof
    Patent number: 9073993
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: July 7, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20140086903
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 27, 2014
    Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
  • Methods of treating drug-resistant cancers
    Patent number: 8512707
    Abstract: Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: August 20, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Charles G. Cerveny, Alan F. Wahl
  • CD3 IMMUNOTHERAPEUTICS AND USES THEREOF
    Publication number: 20130195850
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: November 15, 2012
    Publication date: August 1, 2013
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip TAN, Sandy Alexander SIMON, Charles G. CERVENY, Christy Anne NILSSON, William BRADY, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Peter Armstrong THOMPSON, Cecile MORALES
  • CD19 Binding Agents and Uses Thereof
    Publication number: 20120294853
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: June 21, 2012
    Publication date: November 22, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter, Hans Peter Gerber, Leigh Francisco
  • CD19 binding agents and uses thereof
    Patent number: 8242252
    Abstract: This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: August 14, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter, Hans Peter Gerber, Leigh Francisco
  • CD19 BINDING AGENTS AND USES THEREOF
    Publication number: 20110312088
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: May 17, 2011
    Publication date: December 22, 2011
    Applicant: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter, Hans Peter Gerber, Leigh Francisco
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20110171208
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 11, 2009
    Publication date: July 14, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Philip Tan, Sandy Alexander Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Peter Armstrong Thompson, Cecile Morales
  • CD19 binding agents and uses thereof
    Patent number: 7968687
    Abstract: This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: June 28, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • METHODS OF TREATING DRUG-RESISTANT CANCERS
    Publication number: 20100260786
    Abstract: Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.
    Type: Application
    Filed: April 19, 2010
    Publication date: October 14, 2010
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Charles G. Cerveny, Alan F. Wahl
  • CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF
    Publication number: 20100135900
    Abstract: The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110?-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.
    Type: Application
    Filed: November 13, 2009
    Publication date: June 3, 2010
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: CHARLES G. CERVENY, PETER A. THOMPSON
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20090274692
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 13, 2009
    Publication date: November 5, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Phillip Tan, Sandy A. Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter, Peter A. Thompson, Cecile Morales
  • CD19 Binding Agents and Uses Thereof
    Publication number: 20090136526
    Abstract: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Application
    Filed: October 17, 2008
    Publication date: May 28, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter, Hans-Peter Gerber, Leigh Francisco